Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Neoplasm Metastasis 6Lymphoma, Extranodal NK-T-Cell 6Carcinoma, Hepatocellular 5Stomach Neoplasms 3Nasopharyngeal Carcinoma 3Locally Advanced Rectal Cancer 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Advanced Solid Tumor 3Triple Negative Breast Neoplasms 2Pancreatic Neoplasms 2Neoplasms 2Nasopharyngeal Neoplasms 2Melanoma 2Epstein-Barr Virus Infections 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Pancreatic Adenocarcinoma Metastatic 1Osteosarcoma 1Objective Response Rate 1NSCLC 1Muscle-Invasive Bladder Carcinoma 1Lymphoma, T-Cell 1Lymphoma 1Kidney Neoplasms 1Immunoblastic Lymphadenopathy 1

Interventions

spartalizumab 2pegaspargase 2Methylprednisolone 2Etoposide 2Dexamethasone 2toripalimab 1ruxolitinib 1Valproic Acid 1Valganciclovir 1Rituximab 1Liquid Biopsy 1Lenalidomide 1Gemcitabine 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Epstein-Barr Virus Infections × spartalizumab × Clear all
NCT04084626 2022-01-05

PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV

Beijing Friendship Hospital

Phase 3 Unknown
40 enrolled

Epstein-Barr Virus Infections

NCT05039580 2021-09-09

SEHC

The First Affiliated Hospital of Soochow University

Phase 4 Unknown
36 enrolled

Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡